RNAC

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the advancement and discovery of nanoparticle-based immunomodulatory drugs. These innovative therapeutics are designed to both treat and prevent a variety of human ailments. The company's leading gene therapy initiative, SEL-302, is currently undergoing Phase I clinical trials, with the goal of improving the efficacy of treatment for methylmalonic acidemia. Its product pipeline also features biologic therapies, including SEL-212, which is now in Phase III clinical trials for the management of chronic refractory gout. Furthermore, Selecta is developing candidate therapies specifically aimed at various IgA-mediated conditions, such as IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. Beyond these, the company is progressing gene therapies to address a range of disorders, including Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorders, and other autoimmune conditions. Selecta's research also encompasses tolerogenic therapies, which are developed to target and mitigate autoimmune diseases. The firm has forged strategic alliances and licensing agreements with a diverse group of partners, notably Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Established in 2007, Selecta Biosciences, Inc. maintains its corporate headquarters in Watertown, Massachusetts.